Chemoprevention of inflammation-driven lung cancer

炎症驱动的肺癌的化学预防

基本信息

  • 批准号:
    8815111
  • 负责人:
  • 金额:
    $ 31.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-03-01 至 2016-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chronic pulmonary inflammation is an important risk factor for lung cancer. Accumulating data have shown that smokers with chronic pulmonary inflammation have a higher risk of developing lung cancer as compared to smokers without pulmonary inflammation. Molecular links between pulmonary inflammation and lung cancer are microRNAs (miRs) and pro-inflammatory signaling pathways such as Akt, NF-κB and STAT3. Therefore, targeting of miRs and pro-inflammatory signaling pathways by chemo preventive agents could suppress lung tumor genesis. The main goal of this project is to assess the efficacy of combinations of indole- 3-carbinol (I3C) and silibinin (SB), two widely consumed naturally occurring phytochemicals, to inhibit chronic inflammation-related lung cancer and determine the mechanisms involved. In preliminary studies, we developed a novel and facile mouse model for inflammation-driven lung cancer and showed in in vitro studies with lung cancer cell lines that the ant proliferative and apoptotic effects of I3C plus SB were paralleled b decreased activation of the pro-inflammatory proteins Akt, NF-κB and STAT3, down-regulation of miR-21 and miR-155, but up-regulation of PTEN and SHIP1, targets for miR-21 and miR-155, respectively. Therefore, we hypothesized that inflammation-driven lung tumor genesis could be inhibited by I3C plus SB, at least in part, via modulation of miR-21 and miR-155 levels in association with inhibition of Akt, NF-kB and STAT3 signaling. This hypothesis will be tested by the following three Aims: Specific Aim 1: Evaluate the efficacy of I3C plus SB against NNK plus LPS-induced mouse lung adenocarcinoma, inflammatory milieu and dysregulation of miRs. Specific Aim 2: Determine the efficacy of anti-miR-21 and anti-miR-155, alone or in combination, to inhibit inflammation-driven lung tumor genesis in A/J mice. Specific Aim 3: Elucidate how I3C plus SB interrupts the inflammatory positive feedback loop involving Akt, NF-kB/STAT3, and miR-21/miR155 and thus inhibits cell proliferation and survival. Impact/Significance: The results of this study could establish the basis for future clinical trials of I3C plus SB for lung cancer chemoprevention and provide a better understanding of the molecular events underlying inflammation-driven lung tumor genesis.
描述(由申请人提供):慢性肺部炎症是肺癌的重要风险因素。越来越多的数据表明,与没有肺部炎症的吸烟者相比,患有慢性肺部炎症的吸烟者患肺癌的风险更高。肺部炎症和肺癌之间的分子联系是microRNA(miR)和促炎信号通路如Akt、NF-κB和STAT 3。因此,通过化学预防剂靶向miR和促炎信号传导通路可以抑制肺肿瘤发生。该项目的主要目标是评估吲哚-3-甲醇(I3 C)和水飞蓟宾(SB)(两种广泛使用的天然植物化学物质)组合抑制慢性炎症相关肺癌的疗效,并确定相关机制。在初步研究中,我们开发了一种新的和简单的炎症驱动的肺癌小鼠模型,并在肺癌细胞系的体外研究中显示,I3 C加SB的抗增殖和凋亡作用是显著的,降低了促炎蛋白Akt、NF-κB和STAT 3的活化,下调了miR-21和miR-155,但上调了PTEN和SHIP 1,分别针对miR-21和miR-155。因此,我们假设炎症驱动的肺肿瘤发生可以被I3 C加SB抑制,至少部分是通过调节miR-21和miR-155水平以及抑制Akt、NF-kB和STAT 3信号传导来抑制的。具体目标1:评价I3 C加SB对NNK加LPS诱导的小鼠肺腺癌、炎性环境和miR失调的疗效。具体目标二:确定抗miR-21和抗miR-155单独或组合抑制A/J小鼠中炎症驱动的肺肿瘤发生的功效。具体目标3:阐明I3 C加SB如何中断涉及Akt、NF-kB/STAT 3和miR-21/miR 155的炎症正反馈回路,从而抑制细胞增殖和存活。影响/意义:本研究的结果可以为I3 C加SB用于肺癌化学预防的未来临床试验奠定基础,并提供对炎症驱动的肺肿瘤发生的分子事件的更好理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Fekadu Kassie其他文献

Fekadu Kassie的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Fekadu Kassie', 18)}}的其他基金

Lung cancer prevention and treatment by targeting ALDH1 and CD44 expressing putative lung cancer stem cells
通过靶向表达 ALDH1 和 CD44 的假定肺癌干细胞来预防和治疗肺癌
  • 批准号:
    10478169
  • 财政年份:
    2019
  • 资助金额:
    $ 31.54万
  • 项目类别:
Lung cancer prevention and treatment by targeting ALDH1 and CD44 expressing putative lung cancer stem cells
通过靶向表达 ALDH1 和 CD44 的假定肺癌干细胞来预防和治疗肺癌
  • 批准号:
    10227075
  • 财政年份:
    2019
  • 资助金额:
    $ 31.54万
  • 项目类别:
Lung cancer prevention and treatment by targeting ALDH1 and CD44 expressing putative lung cancer stem cells
通过靶向表达 ALDH1 和 CD44 的假定肺癌干细胞来预防和治疗肺癌
  • 批准号:
    10019474
  • 财政年份:
    2019
  • 资助金额:
    $ 31.54万
  • 项目类别:
Chemoprevention of inflammation-driven lung cancer
炎症驱动的肺癌的化学预防
  • 批准号:
    8435267
  • 财政年份:
    2013
  • 资助金额:
    $ 31.54万
  • 项目类别:
Chemoprevention of inflammation-driven lung cancer
炎症驱动的肺癌的化学预防
  • 批准号:
    9016497
  • 财政年份:
    2013
  • 资助金额:
    $ 31.54万
  • 项目类别:
Diindolylmethane:Inhibition of lung squamous cell carcinoma by targeting Akt.
二吲哚基甲烷:通过靶向 Akt 抑制肺鳞状细胞癌。
  • 批准号:
    8383028
  • 财政年份:
    2012
  • 资助金额:
    $ 31.54万
  • 项目类别:
Diindolylmethane:Inhibition of lung squamous cell carcinoma by targeting Akt.
二吲哚基甲烷:通过靶向 Akt 抑制肺鳞状细胞癌。
  • 批准号:
    8510602
  • 财政年份:
    2012
  • 资助金额:
    $ 31.54万
  • 项目类别:
Lung carcinogenesis: Chemoprevention by Indole-3-carbinol
肺癌发生:3-吲哚甲醇的化学预防
  • 批准号:
    8010146
  • 财政年份:
    2009
  • 资助金额:
    $ 31.54万
  • 项目类别:
Lung carcinogenesis: Chemoprevention by Indole-3-carbinol
肺癌发生:3-吲哚甲醇的化学预防
  • 批准号:
    8409830
  • 财政年份:
    2009
  • 资助金额:
    $ 31.54万
  • 项目类别:
Lung carcinogenesis: Chemoprevention by Indole-3-carbinol
肺癌发生:3-吲哚甲醇的化学预防
  • 批准号:
    7762766
  • 财政年份:
    2009
  • 资助金额:
    $ 31.54万
  • 项目类别:

相似海外基金

The role of alveolar macrophages and regulatory pathways in post-transplant lung inflammation.
肺泡巨噬细胞和调节途径在移植后肺部炎症中的作用。
  • 批准号:
    23K08315
  • 财政年份:
    2023
  • 资助金额:
    $ 31.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
MICA: Key mechanisms underlying inhaled GM-CSF's enhancement of phagocytosis and bacterial clearance by human alveolar macrophages.
MICA:吸入 GM-CSF 增强人肺泡巨噬细胞吞噬作用和细菌清除的关键机制。
  • 批准号:
    MR/X005046/1
  • 财政年份:
    2023
  • 资助金额:
    $ 31.54万
  • 项目类别:
    Research Grant
Analysis of pathogenic alveolar macrophages which release IL-1alpha in response to fine particles.
分析响应细颗粒物释放 IL-1α 的致病性肺泡巨噬细胞。
  • 批准号:
    23H03154
  • 财政年份:
    2023
  • 资助金额:
    $ 31.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Glutamine Metabolism in Alveolar Macrophages following Influenza A Infection
甲型流感感染后肺泡巨噬细胞的谷氨酰胺代谢
  • 批准号:
    10607319
  • 财政年份:
    2023
  • 资助金额:
    $ 31.54万
  • 项目类别:
The function and regulation of tissue resident alveolar macrophages turnover by host and environmental factors during homeostasis and in infections
稳态和感染期间宿主和环境因素对组织驻留肺泡巨噬细胞周转的功能和调节
  • 批准号:
    471247
  • 财政年份:
    2022
  • 资助金额:
    $ 31.54万
  • 项目类别:
    Fellowship Programs
Using a Lung on Chip Device to Study Alveolar Macrophages as Intracellular Reservoirs for Staphylococcus aureus
使用肺芯片装置研究肺泡巨噬细胞作为金黄色葡萄球菌的细胞内储库
  • 批准号:
    485971
  • 财政年份:
    2022
  • 资助金额:
    $ 31.54万
  • 项目类别:
    Studentship Programs
Analysis of innate immune response of alveolar macrophages and epithelial-mesenchymal transition of alveolar epithelial cells
肺泡巨噬细胞的先天免疫反应和肺泡上皮细胞的上皮间质转化分析
  • 批准号:
    22K06698
  • 财政年份:
    2022
  • 资助金额:
    $ 31.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Cholesterol crystal-mediated inflammation in alveolar macrophages: an emerging role inidiopathic lung fibrosis?
胆固醇晶体介导的肺泡巨噬细胞炎症:在特发性肺纤维化中的新兴作用?
  • 批准号:
    462596862
  • 财政年份:
    2021
  • 资助金额:
    $ 31.54万
  • 项目类别:
    WBP Position
Elucidation of idiopathic pneumonia syndrome: Angiotensin 2 activates alveolar macrophages
特发性肺炎综合征的阐明:血管紧张素 2 激活肺泡巨噬细胞
  • 批准号:
    21K16251
  • 财政年份:
    2021
  • 资助金额:
    $ 31.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Establishment of novel macrophage cell lines to study the pathogenesis of respiratory bacterial pathogens in lung alveolar macrophages
建立新型巨噬细胞系以研究肺泡巨噬细胞中呼吸道细菌病原体的发病机制
  • 批准号:
    NC/V001019/1
  • 财政年份:
    2021
  • 资助金额:
    $ 31.54万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了